Dihomo-γ-linolenic acid prevents the development of atopic dermatitis through prostaglandin D1 production in NC/Tnd mice

Journal of Dermatological Science

Volumn 79, Issue 1, 2015, Pages 30-37

  Amagai, Yosuke ^a   Oida, Kumiko ^a   Matsuda, Akira ^b   Jung, Kyungsook ^a   Kakutani, Saki ^c   Tanaka, Takao ^c   Matsuda, Kenshiro ^a   Jang, Hyosun ^a   Ahn, Ginae ^a   Xia, Yan ^a   Kawashima, Hiroshi ^c   Shibata, Hiroshi ^c   Matsuda, Hiroshi ^a,b   Tanaka, Akane ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b Laboratory of Veterinary Molecular Pathology and Therapeutics Division of Animal Life Science Institute of Agriculture   (Japan)

^c Suntory Wellness Limited Research Center   (Japan)

Author keywords

Atopic dermatitis; Dihomo linolenic acid; NC Tnd mouse; Prostaglandin D1

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN E; PROSTAGLANDIN; PROSTAGLANDIN D1; PROSTAGLANDIN D2; THYMIC STROMAL LYMPHOPOIETIN; UNCLASSIFIED DRUG; CYTOKINE; MESSENGER RNA; PROSTAGLANDIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; IN VIVO STUDY; KERATINOCYTE; LIPID DIET; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROSTAGLANDIN SYNTHESIS; SCRATCHING; SKIN PRURITUS; SUPPLEMENTATION; ANIMAL; BIOSYNTHESIS; CUTANEOUS DRUG ADMINISTRATION; DEGRANULATION; DERMATITIS, ATOPIC; DIETARY SUPPLEMENT; DRUG EFFECTS; GENETICS; MAST CELL; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); UPREGULATION;

8,11,14-EICOSATRIENOIC ACID; ADMINISTRATION, CUTANEOUS; ANIMALS; ARACHIDONIC ACID; CELL DEGRANULATION; CYTOKINES; DERMATITIS, ATOPIC; DIETARY SUPPLEMENTS; EICOSAPENTAENOIC ACID; GENE EXPRESSION; MAST CELLS; MICE; PROSTAGLANDIN D2; PROSTAGLANDINS D; RNA, MESSENGER; UP-REGULATION;

EID: 84929955957     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2015.03.010     Document Type: Article

References (42)

1. Ring J., Alomar A., Bieber T., Deleuran M., Fink-Wagner A., Gelmetti C., et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012, 26:1045-1060.
2. Schmid-Ott G., Jaeger B., Kapp A., Werfel T. Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls. J Allergy Clin Immunol 2001, 108:455-462.
3. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
4. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J., Lane M.E., Moustafa M., et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129:1892-1908.
5. Schäfer L., Kragballe K. Abnormalities in epidermal lipid metabolism in patients with atopic dermatitis. J Invest Dermatol 1991, 96:10-15.
6. Trak-Fellermeier M.A., Brasche S., Winkler G., Koletzko B., Heinrich J. Food and fatty acid intake and atopic disease in adults. Eur Respir J 2004, 23:575-582.
7. Sala-Vila A., Miles E., Calder P. Fatty acid composition abnormalities in atopic disease: evidence explored and role in the disease process examined. Clin Exp Allergy 2008, 38:1432-1450.
8. Berth-Jones J., Graham-Brown R. Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis. Lancet 1993, 341:1557-1560.
9. Van Gool C., Zeegers M., Thijs C. Oral essential fatty acid supplementation in atopic dermatitis-a meta-analysis of placebo-controlled trials. Br J Dermatol 2004, 150:728-740.
10. 1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2004, 505:229-235.
11. 2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol 2005, 518:56-62.
12. 2 biosynthesis in NC/Nga mice with atopic dermatitis. Exp Dermatol 2005, 14:898-905.
13. 2 production on atopic-like scratching behaviour in mice. Exp Dermatol 2007, 16:331-339.
14. 2 level in the skin of NC/Nga mice. Eur J Pharmacol 2007, 564:196-203.
15. Kawashima H., Tateishi N., Shiraishi A., Teraoka N., Tanaka T., Tanaka A., et al. Oral administration of dihomo-γ-linolenic acid prevents development of atopic dermatitis in NC/Nga mice. Lipids 2008, 43:37-43.
16. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009, 49:123-150.
17. 2. Br J Pharmacol 1975, 55:239-240.
18. Matsuda H., Watanabe N., Geba G.P., Sperl J., Tsudzuki M., Hiroi J., et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997, 9:461-466.
19. Orito K., Chida Y., Fujisawa C., Arkwright P., Matsuda H. A new analytical system for quantification scratching behaviour in mice. Br J Dermatol 2004, 150:33-38.
20. Kakutani S., Kawashima H., Tanaka T., Shiraishi-Tateishi A., Kiso Y. Uptake of dihomo-γ-linolenic acid by murine macrophages increases series-1 prostaglandin release following lipopolysaccharide treatment. Prostaglandins Leukot Essent Fatty Acids 2010, 83:23-29.
21. 2 content in murine colitis model. Lipids Health Dis 2014, 13:30.
22. Morita Y., Siraganian R.P. Inhibition of IgE-mediated histamine release from rat basophilic leukemia cells and rat mast cells by inhibitors of transmethylation. J Immunol 1981, 127:1339-1344.
23. Ortega E., Hazan B., Zor U., Pecht I. Mast cell stimulation by monoclonal antibodies specific for the Fc epsilon receptor yields distinct responses of arachidonic acid and leukotriene C4 secretion. Eur J Immunol 1989, 19:2251-2256.
24. Amagai Y., Tanaka A., Ohmori K., Matsuda H. Establishment of a novel high-affinity IgE receptor-positive canine mast cell line with wild-type c-kit receptors. Biochem Biophys Res Commun 2008, 366:857-861.
25. Terranova V.P., Rohrbach D.H., Martin G.R. Role of laminin in the attachment of PAM 212 (epithelial) cells to basement membrane collagen. Cell 1980, 22:719-726.
26. Benyon R.C., Robinson C., Holgate S.T., Church M.K. Prostaglandin D2 release from human skin mast cells in response to ionophore A23187. Br J Pharmacol 1987, 92:635-638.
27. Benyon R.C., Robinson C., Church M.K. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br J Pharmacol 1989, 97:898-904.
28. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat Immunol 2002, 3:673-680.
29. H2 central memory t cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 2006, 24:827-838.
30. Chisaguano A.M., Montes R., Pérez-Berezo T., Castellote A.I., Guerendiain M., Bustamante M., et al. Gene expression of desaturase (FADS1 and FADS2) and elongase (ELOVL5) enzymes in peripheral blood: association with polyunsaturated fatty acid levels and atopic eczema in 4-year-old children. PLoS ONE 2013, 8:e78245.
31. Kim N., Luster A.D. Regulation of immune cells by eicosanoid receptors. Sci World J 2007, 7:1307-1328.
32. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001, 98:1942-1948.
33. 2 receptor-mediated functions. J Exp Med 2004, 199:1317-1330.
34. Fujitani Y., Kanaoka Y., Aritake K., Uodome N., Okazaki-Hatake K., Urade Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002, 168:443-449.
35. 2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem 2006, 6:1427-1444.
36. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995, 270:23975-23983.
37. 2-supplemented media. Neurochem Int 1988, 12:5-12.
38. Hata A.N., Zent R., Breyer M.D., Breyer R.M. Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther 2003, 306:463-470.
39. Hirai H., Tanaka K., Yoshie O., Ogawa K., Kenmotsu K., Takamori Y., et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001, 193:255-261.
40. Serra-Pages M., Olivera A., Torres R., Picado C., de Mora F., Rivera J. E-prostanoid 2 receptors dampen mast cell degranulation via cAMP/PKA-mediated suppression of IgE-dependent signaling. J Leukoc Biol 2012, 92:1155-1165.
41. Yoshimura M., Cooper D.M. Type-specific stimulation of adenylylcyclase by protein kinase C. J Biol Chem 1993, 268:4604-4607.
42. Vergroesen A.J. Physiological effects of dietary linoleic acid. Nutr Rev 1977, 35:1-5.